Is SINT or TELA more profitable?

TELA Bio has a net margin of -49.30% compared to Sintx Technologies' net margin of -1,058.60%. Sintx Technologies' return on equity of -366.49% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets Sintx Technologies -1,058.60% -366.49% -115.04% TELA Bio -49.30% -1,320.81% -55.83%

Is NEPH or SINT more profitable?

Nephros has a net margin of 4.06% compared to Sintx Technologies' net margin of -1,058.60%. Nephros' return on equity of 7.66% beat Sintx Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% Sintx Technologies -1,058.60% -366.49% -115.04%

Does the media prefer NEPH or SINT?

In the previous week, Nephros and Nephros both had 1 articles in the media. Nephros' average media sentiment score of 0.03 beat Sintx Technologies' score of 0.00 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sintx Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PSTV or SINT?

In the previous week, Plus Therapeutics and Plus Therapeutics both had 1 articles in the media. Plus Therapeutics' average media sentiment score of 0.00 equaled Sintx Technologies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sintx Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SINT or NSPR more profitable?

InspireMD has a net margin of -413.96% compared to Sintx Technologies' net margin of -1,058.60%. InspireMD's return on equity of -69.42% beat Sintx Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Sintx Technologies -1,058.60% -366.49% -115.04% InspireMD -413.96% -69.42% -57.68%

Does the media favor SINT or NSPR?

In the previous week, InspireMD had 1 more articles in the media than Sintx Technologies. MarketBeat recorded 2 mentions for InspireMD and 1 mentions for Sintx Technologies. Sintx Technologies' average media sentiment score of 0.00 equaled InspireMD'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sintx Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InspireMD 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SINT or PETV?

Sintx Technologies currently has a consensus price target of $9.33, suggesting a potential upside of 386.11%. Given Sintx Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe Sintx Technologies is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SINT or PETV more profitable?

PetVivo has a net margin of -902.82% compared to Sintx Technologies' net margin of -1,058.60%. Sintx Technologies' return on equity of -366.49% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets Sintx Technologies -1,058.60% -366.49% -115.04% PetVivo -902.82% -4,813.07% -281.78%

Sintx Technologies (SINT) Competitors

$1.92 -0.07 (-3.52%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$1.94 +0.02 (+0.99%)

As of 06/23/2026 06:59 PM Eastern

Compare

SINT vs. TELA, NEPH, PSTV, NSPR, and PETV

Should you buy Sintx Technologies stock or one of its competitors? MarketBeat compares Sintx Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sintx Technologies include TELA Bio (TELA), Nephros (NEPH), Plus Therapeutics (PSTV), InspireMD (NSPR), and PetVivo (PETV). These companies are all part of the "medical equipment" industry.

How does Sintx Technologies compare to TELA Bio?

Sintx Technologies (NASDAQ:SINT) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Sintx Technologies presently has a consensus target price of $9.33, suggesting a potential upside of 386.11%. TELA Bio has a consensus target price of $2.20, suggesting a potential upside of 179.97%. Given Sintx Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Sintx Technologies is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

18.4% of Sintx Technologies shares are held by institutional investors. Comparatively, 94.4% of TELA Bio shares are held by institutional investors. 4.1% of Sintx Technologies shares are held by insiders. Comparatively, 5.1% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sintx Technologies has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, TELA Bio has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

In the previous week, Sintx Technologies had 1 more articles in the media than TELA Bio. MarketBeat recorded 1 mentions for Sintx Technologies and 0 mentions for TELA Bio. Sintx Technologies' average media sentiment score of 0.00 equaled TELA Bio'saverage media sentiment score.

Company	Overall Sentiment
Sintx Technologies	Neutral
TELA Bio	Neutral

TELA Bio has a net margin of -49.30% compared to Sintx Technologies' net margin of -1,058.60%. Sintx Technologies' return on equity of -366.49% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-1,058.60%	-366.49%	-115.04%
TELA Bio	-49.30%	-1,320.81%	-55.83%

Sintx Technologies has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02M	8.13	-$10.36M	-$5.07	N/A
TELA Bio	$80.28M	0.44	-$38.83M	-$0.79	N/A

Summary

Sintx Technologies and TELA Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Sintx Technologies compare to Nephros?

Nephros (NASDAQ:NEPH) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, Nephros and Nephros both had 1 articles in the media. Nephros' average media sentiment score of 0.03 beat Sintx Technologies' score of 0.00 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sintx Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nephros has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Nephros has a net margin of 4.06% compared to Sintx Technologies' net margin of -1,058.60%. Nephros' return on equity of 7.66% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Sintx Technologies	-1,058.60%	-366.49%	-115.04%

Nephros has higher revenue and earnings than Sintx Technologies. Sintx Technologies is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$19.12M	1.87	$1.19M	$0.07	47.14
Sintx Technologies	$1.02M	8.13	-$10.36M	-$5.07	N/A

41.1% of Nephros shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 4.1% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nephros presently has a consensus price target of $6.00, indicating a potential upside of 81.82%. Sintx Technologies has a consensus price target of $9.33, indicating a potential upside of 386.11%. Given Sintx Technologies' higher probable upside, analysts plainly believe Sintx Technologies is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Nephros beats Sintx Technologies on 11 of the 14 factors compared between the two stocks.

How does Sintx Technologies compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 4.1% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Plus Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Plus Therapeutics and Plus Therapeutics both had 1 articles in the media. Plus Therapeutics' average media sentiment score of 0.00 equaled Sintx Technologies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sintx Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Plus Therapeutics currently has a consensus target price of $56.40, indicating a potential upside of 1,282.35%. Sintx Technologies has a consensus target price of $9.33, indicating a potential upside of 386.11%. Given Plus Therapeutics' higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Sintx Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Sintx Technologies has lower revenue, but higher earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.39	-$22.39M	-$2.30	N/A
Sintx Technologies	$1.02M	8.13	-$10.36M	-$5.07	N/A

Plus Therapeutics has a net margin of -230.24% compared to Sintx Technologies' net margin of -1,058.60%. Plus Therapeutics' return on equity of -198.48% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Sintx Technologies	-1,058.60%	-366.49%	-115.04%

Summary

Plus Therapeutics beats Sintx Technologies on 8 of the 14 factors compared between the two stocks.

How does Sintx Technologies compare to InspireMD?

Sintx Technologies (NASDAQ:SINT) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Sintx Technologies has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, InspireMD has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Sintx Technologies presently has a consensus target price of $9.33, suggesting a potential upside of 386.11%. InspireMD has a consensus target price of $4.50, suggesting a potential upside of 541.94%. Given InspireMD's stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Sintx Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

18.4% of Sintx Technologies shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 4.1% of Sintx Technologies shares are held by insiders. Comparatively, 34.1% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, InspireMD had 1 more articles in the media than Sintx Technologies. MarketBeat recorded 2 mentions for InspireMD and 1 mentions for Sintx Technologies. Sintx Technologies' average media sentiment score of 0.00 equaled InspireMD'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sintx Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InspireMD	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InspireMD has a net margin of -413.96% compared to Sintx Technologies' net margin of -1,058.60%. InspireMD's return on equity of -69.42% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-1,058.60%	-366.49%	-115.04%
InspireMD	-413.96%	-69.42%	-57.68%

Sintx Technologies has higher earnings, but lower revenue than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02M	8.13	-$10.36M	-$5.07	N/A
InspireMD	$10.85M	3.03	-$19.92M	-$0.73	N/A

Summary

InspireMD beats Sintx Technologies on 11 of the 14 factors compared between the two stocks.

How does Sintx Technologies compare to PetVivo?

Sintx Technologies (NASDAQ:SINT) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

18.4% of Sintx Technologies shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 4.1% of Sintx Technologies shares are held by company insiders. Comparatively, 10.8% of PetVivo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sintx Technologies has higher earnings, but lower revenue than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02M	8.13	-$10.36M	-$5.07	N/A
PetVivo	$1.05M	28.73	-$10.95M	-$0.38	N/A

In the previous week, Sintx Technologies had 1 more articles in the media than PetVivo. MarketBeat recorded 1 mentions for Sintx Technologies and 0 mentions for PetVivo. Sintx Technologies' average media sentiment score of 0.00 equaled PetVivo'saverage media sentiment score.

Company	Overall Sentiment
Sintx Technologies	Neutral
PetVivo	Neutral

PetVivo has a net margin of -902.82% compared to Sintx Technologies' net margin of -1,058.60%. Sintx Technologies' return on equity of -366.49% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-1,058.60%	-366.49%	-115.04%
PetVivo	-902.82%	-4,813.07%	-281.78%

Sintx Technologies currently has a consensus price target of $9.33, suggesting a potential upside of 386.11%. Given Sintx Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe Sintx Technologies is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Sintx Technologies has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, PetVivo has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

Summary

Sintx Technologies beats PetVivo on 8 of the 15 factors compared between the two stocks.

Get Sintx Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SINT vs. The Competition

Export

Metric	Sintx Technologies	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.60M	$7.05B	$6.44B	$12.39B
Dividend Yield	N/A	1.28%	2.69%	5.83%
P/E Ratio	-0.38	48.65	24.66	23.99
Price / Sales	8.13	76.50	528.64	107.77
Price / Cash	N/A	24.78	44.82	54.51
Price / Book	2.40	7.13	10.79	6.50
Net Income	-$10.36M	$159.20M	$3.56B	$336.88M
7 Day Performance	-7.69%	-0.98%	1.01%	-0.14%
1 Month Performance	-19.67%	-1.97%	0.43%	0.77%
1 Year Performance	-38.26%	5.08%	29.71%	28.49%

Sintx Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SINT Sintx Technologies	2.8591 of 5 stars	$1.92 -3.5%	$9.33 +386.1%	-37.5%	$8.60M	$1.02M	N/A	40
TELA TELA Bio	2.306 of 5 stars	$0.90 +12.2%	$2.20 +145.2%	-54.6%	$35.81M	$80.28M	N/A	120	Positive News
NEPH Nephros	2.3142 of 5 stars	$3.19 +1.9%	$6.00 +88.1%	-23.1%	$33.98M	$18.79M	45.58	30	Positive News High Trading Volume
PSTV Plus Therapeutics	1.8103 of 5 stars	$4.57 -5.8%	$56.40 +1,134.1%	-11.4%	$33.39M	$5.21M	N/A	20
NSPR InspireMD	4.0799 of 5 stars	$0.71 -6.3%	$4.50 +531.7%	-72.2%	$33.37M	$10.85M	N/A	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SINT) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sintx Technologies (SINT) Competitors

SINT vs. TELA, NEPH, PSTV, NSPR, and PETV

How does Sintx Technologies compare to TELA Bio?

Summary

How does Sintx Technologies compare to Nephros?

Summary

How does Sintx Technologies compare to Plus Therapeutics?

Summary

How does Sintx Technologies compare to InspireMD?

Summary

How does Sintx Technologies compare to PetVivo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SINT vs. The Competition

Sintx Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sintx Technologies (SINT) Competitors

SINT vs. TELA, NEPH, PSTV, NSPR, and PETV

How does Sintx Technologies compare to TELA Bio?

Do analysts recommend SINT or TELA?

Do insiders & institutionals hold more shares of SINT or TELA?

Which has more volatility & risk, SINT or TELA?

Does the media refer more to SINT or TELA?

Is SINT or TELA more profitable?

Which has preferable earnings and valuation, SINT or TELA?

Summary

How does Sintx Technologies compare to Nephros?

Does the media prefer NEPH or SINT?

Which has more volatility & risk, NEPH or SINT?

Is NEPH or SINT more profitable?

Which has better earnings & valuation, NEPH or SINT?

Do insiders and institutionals believe in NEPH or SINT?

Do analysts rate NEPH or SINT?

Summary

How does Sintx Technologies compare to Plus Therapeutics?

Do insiders & institutionals have more ownership in PSTV or SINT?

Which has more volatility and risk, PSTV or SINT?

Does the media prefer PSTV or SINT?

Do analysts rate PSTV or SINT?

Which has higher valuation & earnings, PSTV or SINT?

Is PSTV or SINT more profitable?

Summary

How does Sintx Technologies compare to InspireMD?

Which has more volatility and risk, SINT or NSPR?

Do analysts prefer SINT or NSPR?

Do insiders and institutionals hold more shares of SINT or NSPR?

Does the media favor SINT or NSPR?

Is SINT or NSPR more profitable?

Which has better valuation and earnings, SINT or NSPR?

Summary

How does Sintx Technologies compare to PetVivo?

Do institutionals & insiders hold more shares of SINT or PETV?

Which has higher earnings & valuation, SINT or PETV?

Does the media refer more to SINT or PETV?

Is SINT or PETV more profitable?

Do analysts prefer SINT or PETV?

Which has more risk & volatility, SINT or PETV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SINT vs. The Competition

Sintx Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools